HK1208818A1 - Heteroaryl ketone fused azadecalin glucocorticoid receptor modulators - Google Patents

Heteroaryl ketone fused azadecalin glucocorticoid receptor modulators

Info

Publication number
HK1208818A1
HK1208818A1 HK15109587.3A HK15109587A HK1208818A1 HK 1208818 A1 HK1208818 A1 HK 1208818A1 HK 15109587 A HK15109587 A HK 15109587A HK 1208818 A1 HK1208818 A1 HK 1208818A1
Authority
HK
Hong Kong
Prior art keywords
receptor modulators
glucocorticoid receptor
fused azadecalin
heteroaryl ketone
ketone fused
Prior art date
Application number
HK15109587.3A
Other languages
English (en)
Chinese (zh)
Inventor
Hazel Hunt
Tony Johnson
Nicholas Ray
Iain Walters
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of HK1208818A1 publication Critical patent/HK1208818A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Electroluminescent Light Sources (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15109587.3A 2012-05-25 2015-09-29 Heteroaryl ketone fused azadecalin glucocorticoid receptor modulators HK1208818A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261651669P 2012-05-25 2012-05-25
US201261691083P 2012-08-20 2012-08-20
US201261715907P 2012-10-19 2012-10-19
US201361759520P 2013-02-01 2013-02-01
US201361781629P 2013-03-14 2013-03-14
PCT/US2013/042732 WO2013177559A2 (en) 2012-05-25 2013-05-24 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
HK1208818A1 true HK1208818A1 (en) 2016-03-18

Family

ID=49624542

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15109587.3A HK1208818A1 (en) 2012-05-25 2015-09-29 Heteroaryl ketone fused azadecalin glucocorticoid receptor modulators
HK18109510.2A HK1250014B (zh) 2012-05-25 2018-07-23 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18109510.2A HK1250014B (zh) 2012-05-25 2018-07-23 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑

Country Status (23)

Country Link
EP (6) EP4434584A2 (xx)
JP (1) JP6172871B2 (xx)
KR (1) KR102062640B1 (xx)
CN (1) CN104619328B (xx)
AU (1) AU2013266110C1 (xx)
BR (1) BR112014028857B1 (xx)
CA (1) CA2872260C (xx)
CL (1) CL2014003173A1 (xx)
DK (5) DK3590517T3 (xx)
ES (4) ES2873949T3 (xx)
HK (2) HK1208818A1 (xx)
IL (1) IL235868A (xx)
MX (1) MX365423B (xx)
MY (1) MY172739A (xx)
NZ (1) NZ701469A (xx)
PE (1) PE20150352A1 (xx)
PH (1) PH12014502584A1 (xx)
PL (4) PL3590517T3 (xx)
PT (5) PT3338781T (xx)
RU (1) RU2639867C2 (xx)
SG (1) SG11201407682TA (xx)
WO (1) WO2013177559A2 (xx)
ZA (1) ZA201408182B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11925626B2 (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP6516743B2 (ja) * 2013-11-25 2019-05-22 コーセプト セラピューティクス， インコーポレイテッド オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
EP3265127B1 (en) * 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
US10604807B2 (en) 2015-05-18 2020-03-31 Corcept Therapeutics, Inc. Methods for diagnosing and assessing treatment for Cushing's syndrome
JP6768789B2 (ja) 2015-08-13 2020-10-14 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ依存性クッシング症候群を鑑別診断する方法
US10980797B2 (en) * 2016-03-01 2021-04-20 Corcept Therapeutics Incorporated Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
US10413540B2 (en) 2017-03-31 2019-09-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
EP3641780A4 (en) * 2017-06-20 2021-02-24 Corcept Therapeutics, Inc. TREATMENT METHODS OF NEURO-EPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
AU2019261274B2 (en) * 2018-04-23 2021-10-28 Corcept Therapeutics, Inc. Methods of preparing regioselective N-alkyl triazoles
CN113015528A (zh) 2018-11-09 2021-06-22 科塞普特治疗公司 缩小垂体肿瘤的方法
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3122581A1 (en) * 2018-12-20 2020-06-25 Corcept Therapeutics Incorporated Methods for imaging and treatment of somatostatin-receptor positive tumors
CN113490496A (zh) * 2019-02-22 2021-10-08 科赛普特治疗学股份有限公司 一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途
CN114650820A (zh) * 2019-10-16 2022-06-21 科赛普特治疗学股份有限公司 通过选择性糖皮质激素受体拮抗剂使癌症患者的中性粒细胞对淋巴细胞比例正常化的方法
WO2021119432A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
WO2021127376A1 (en) 2019-12-21 2021-06-24 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
TW202246260A (zh) * 2021-02-03 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用
US20240131020A1 (en) * 2022-10-06 2024-04-25 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
WO2024173745A1 (en) * 2023-02-17 2024-08-22 Corcept Therapeutics Incorporated Methods and compositions for treating huntington's disease and its symptoms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
DK1735308T3 (da) 2004-03-09 2009-01-19 Corcept Therapeutics Inc Kondenserede azadecalinringe som glucocorticoidreceptormodulatorer
US7640389B2 (en) 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
KR20130106378A (ko) * 2010-08-27 2013-09-27 코어셉트 쎄라퓨틱스, 잉크. 피리딜-아민 융합된 아자데칼린 조절제

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11925626B2 (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

Also Published As

Publication number Publication date
MY172739A (en) 2019-12-11
EP2854814A4 (en) 2016-01-27
DK3338781T3 (da) 2019-12-09
EP2854814A2 (en) 2015-04-08
HK1250014B (zh) 2020-06-12
PL3338781T3 (pl) 2020-03-31
PL2854814T3 (pl) 2018-07-31
PT3851107T (pt) 2022-10-28
AU2013266110B2 (en) 2017-04-20
SG11201407682TA (en) 2014-12-30
AU2013266110C1 (en) 2018-07-12
PH12014502584B1 (en) 2015-01-21
WO2013177559A2 (en) 2013-11-28
KR20150021955A (ko) 2015-03-03
EP3851107B1 (en) 2022-10-19
EP3590517A1 (en) 2020-01-08
PT3590517T (pt) 2021-04-07
EP4434584A2 (en) 2024-09-25
ES2753816T3 (es) 2020-04-14
IL235868A0 (en) 2015-01-29
EP2854814B1 (en) 2018-01-31
ES2873949T3 (es) 2021-11-04
DK3590517T3 (da) 2021-05-03
CA2872260A1 (en) 2013-11-28
PL3851107T3 (pl) 2023-03-06
RU2014152625A (ru) 2016-07-20
MX2014014239A (es) 2015-08-05
EP3338781A1 (en) 2018-06-27
DK4119561T3 (da) 2024-09-30
CL2014003173A1 (es) 2015-02-27
PT2854814T (pt) 2018-03-15
KR102062640B1 (ko) 2020-01-06
DK3851107T3 (da) 2022-11-21
PE20150352A1 (es) 2015-03-16
JP6172871B2 (ja) 2017-08-02
CN104619328A (zh) 2015-05-13
EP4119561A1 (en) 2023-01-18
AU2013266110A1 (en) 2014-11-20
PH12014502584A1 (en) 2015-01-21
PT3338781T (pt) 2019-11-29
BR112014028857B1 (pt) 2021-09-28
WO2013177559A3 (en) 2014-01-16
JP2015517580A (ja) 2015-06-22
PL3590517T3 (pl) 2021-09-20
ZA201408182B (en) 2017-09-27
ES2665338T3 (es) 2018-04-25
IL235868A (en) 2017-12-31
BR112014028857A2 (pt) 2017-08-15
CA2872260C (en) 2020-12-22
RU2639867C2 (ru) 2017-12-25
MX365423B (es) 2019-06-03
EP3590517B1 (en) 2021-03-17
EP3851107A1 (en) 2021-07-21
DK2854814T3 (en) 2018-03-12
NZ701469A (en) 2017-06-30
PT4119561T (pt) 2024-09-30
EP4119561B1 (en) 2024-09-11
EP3338781B1 (en) 2019-09-11
CN104619328B (zh) 2018-10-02
ES2930298T3 (es) 2022-12-09

Similar Documents

Publication Publication Date Title
HK1250014B (zh) 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑
ZA201604026B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
EP2609097A4 (en) AZADECALINE PYRIDYL-AMINE MODULATORS
HK1223353A1 (zh) 受體調節劑
HK1209744A1 (en) Novel selective androgen receptor modulators
IL235557B (en) Modulators of 17 gpr receptors
EP2935284A4 (en) HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
HUE038700T2 (hu) Benzofuran-2-szulfonamid származékok, mint kemokinreceptor-modulációk
EP2892527A4 (en) HETEROCYCLIC MODULATORS OF NUCLEAR HORMONAL RECEPTORS